Thomas Harding - 01 Feb 2022 Form 4 Insider Report for Clovis Oncology, Inc.

Role
Senior Vice President and Chief Scientific Officer
Signature
/s/ Thomas Harding
Issuer symbol
N/A
Transactions as of
01 Feb 2022
Net transactions value
-$4,108
Form type
4
Filing time
03 Feb 2022, 15:15:59 UTC
Previous filing
04 Jan 2022
Next filing
03 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +1,563 +29% 6,958 01 Feb 2022 Direct F1
transaction CLVS Common Stock Sale $1,829 -943 -14% $1.94* 6,015 02 Feb 2022 Direct F2, F3
transaction CLVS Common Stock Options Exercise +1,813 +30% 7,828 01 Feb 2022 Direct F1
transaction CLVS Common Stock Sale $2,122 -1,094 -14% $1.94* 6,734 02 Feb 2022 Direct F2, F3
transaction CLVS Common Stock Options Exercise +182 +12% 1,733 01 Feb 2022 By wife F1
transaction CLVS Common Stock Sale $157 -81 -4.7% $1.94* 1,652 02 Feb 2022 By wife F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 -1,563 -20% $0.000000 6,250 01 Feb 2022 Common Stock 1,563 Direct F1, F5
transaction CLVS Restricted Stock Units Options Exercise $0 -1,813 -11% $0.000000 14,500 01 Feb 2022 Common Stock 1,813 Direct F1, F6
transaction CLVS Restricted Stock Units Options Exercise $0 -182 -11% $0.000000 1,450 01 Feb 2022 Common Stock 182 By wife F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 On February 1, 2019, the reporting person was granted 25,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F6 On January 31, 2020, the reporting person was granted 29,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F7 On January 31, 2020, the reporting person's wife was granted 2,900 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Senior Vice President and Chief Scientific Officer